MicrobiomX is focused on leveraging the gut microbiome's potential to improve health outcomes in both human and animal medicine. Their innovative approach includes the development of the Tend device, which simplifies the collection, preparation, and encapsulation of microbiome material from stool samples for therapeutic use. This device aims to address the challenges associated with traditional methods of processing stool samples, which can be invasive, expensive, and complex. By providing a clean and efficient way to prepare microbiome material, Tend facilitates easier access for researchers, clinicians, and patients, ultimately promoting healing from within.

The company recognizes the significant impact that disruptions to the gut microbiome can have on overall health, particularly in the context of common medical treatments like antibiotics and chemotherapy. MicrobiomX's efforts are directed towards mainstreaming microbiome-based therapies, with a focus on establishing a baseline understanding of what constitutes a healthy microbiome. Their work includes engaging with the research community and exploring the potential for future applications, such as banking an individual's microbiome for later therapeutic use. Through these initiatives, MicrobiomX aims to expand the understanding and utilization of the gut microbiome in clinical settings.

United States

Fecal microbiota transplant (FMT) has been gaining traction among healthcare providers, researchers, and patients, with hundreds of clinical trials underway and compelling data on FMT benefits for a variety of medical conditions, far beyond its initial application for Clostridium difficile. However, existing FMT treatment methods are time consuming, costly, and sometimes invasive. The team at MicrobiomX recognized the opportunity to develop a scalable, safe, rapid FMT solution.

MicrobiomX

Company Details